Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Outcome in schizophrenia: beyond symptom reduction.

H Y Meltzer1

  • 1Department of Psychopharmacology, Vanderbilt University School of Medicine, Nashville, Tenn 37212, USA.

The Journal of Clinical Psychiatry
|March 12, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.

Journal of neurochemistry·1996
Same author

Genetic variation of 5-HT2A receptor and response to clozapine.

Lancet (London, England)·1995
Same author

Neuropeptide Y in frontal cortex is not altered in major depression.

Journal of neurochemistry·1995
Same author

Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men.

Biological psychiatry·1995
Same author

Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia.

Archives of general psychiatry·1995
Same author

Effect of antidepressants on striatal and accumbens extracellular dopamine levels.

European journal of pharmacology·1995

Atypical antipsychotics improve schizophrenia outcomes by reducing symptoms, side effects, and cognitive impairment. This enhances quality of life and may restore patient productivity, offering societal cost-effectiveness.

Area of Science:

  • Psychiatry and Pharmacology
  • Health Economics

Background:

  • Schizophrenia often leads to chronic illness and significant societal economic burden.
  • Current healthcare allocations for schizophrenia treatment are substantial.

Purpose of the Study:

  • To evaluate the clinical outcome and cost-effectiveness of atypical antipsychotics in schizophrenia.
  • To assess the impact of atypical antipsychotics on various meaningful outcome measures.

Main Methods:

  • Comprehensive assessment of clinical outcomes.
  • Evaluation of cost-effectiveness in the context of patient recovery and productivity.

Main Results:

  • Atypical antipsychotics reduce positive and negative symptoms with fewer side effects than conventional neuroleptics.

Related Experiment Videos

  • Evidence suggests improvements in cognitive function, quality of life, and mood.
  • These agents offer potential for improved patient outcomes and societal cost savings.

    • Conclusions:

    • Atypical antipsychotics, especially with psychosocial treatment, show promise for better schizophrenia outcomes.
    • Increased availability of atypical agents could be cost-effective by restoring patient productivity.